The article from the World Health Organization (WHO) Regional Office for Africa, titled “Urgent action needed to reinforce breast cancer control measures in Africa: WHO report,” highlights critical issues and recommendations regarding breast cancer in Africa. This report brings attention to the urgent need for improved control measures to combat the rising burden of the disease across the continent.
The report estimates that if current trends continue, approximately 135,000 women in sub-Saharan Africa could lose their lives to breast cancer by 2040. The WHO study assessed breast cancer control capacities in 42 out of the 47 countries in the African region. It focused on six vital areas: leadership, governance and financing, health workforce, health information systems, and service delivery. Africa faces significant gaps and disparities in breast cancer control, with critical challenges affecting prevention, diagnosis, and treatment. A severe shortage of healthcare workers limits essential services, while access to specialised cancer centers remains inadequate. Only 5 out of 47 countries have organised breast cancer screening programs, forcing most to rely on opportunistic screening. Pathology services are also insufficient, with only two countries meeting the standard of one laboratory per 100,000 people. These gaps hinder early detection and effective treatment, contributing to high mortality rates.
Late diagnoses and poor prevention efforts drive high breast cancer mortality. In 2022, Africa recorded 38 new cases and 19 deaths per 100,000 women. The report calls for urgent investments in leadership, governance, and financing to improve breast cancer care. Countries must develop and fund National Cancer Control Plans for coordinated action. Expanding oncology training is crucial to address the severe shortage of cancer professionals. Organised screening and early diagnosis programs must be accessible to all women, as early detection greatly improves survival rates. A multi-faceted approach is essential to strengthen healthcare infrastructure, train more professionals, and ensure equitable access to life-saving services.
🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!
#SyenzaNews #globalhealth #healthcareInnovation
🌍 Can collaboration redefine Africa’s health landscape?
A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.
Look into the details of this transformative partnership and its implications for the future of healthcare in the region!
#SyenzaNews #globalhealth #HealthcareInnovation
🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?
A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.
Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.
#SyenzaNews #globalhealth #oncology #HealthTech
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
